Company intelligence / Profile preview

Shanghai Xianshang Pharmaceutical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Commercial

Overview

Shanghai Xianshang Pharmaceutical Technology is a clinical-stage biotech focused on oncology and related indications. All lead assets are in Phase 1 as of early/mid 2025. The company leverages advanced modalities such as antibody-drug conjugates and trispecific T-cell engagers targeting novel mechanisms including POLQ inhibition and multi-antigen targeting in hematologic malignancies.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateSmall moleculeTrispecific T-cell engagerFusion protein
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Xianshang Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Xianshang Pharmaceutical Technology.

Explore the full profile